Q3001 HCPCS Level II code: Radioelements for brachytherapy, any type, each
Q3001 is the HCPCS code for “Radioelements for brachytherapy, any type, each” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q3001Radioelements for brachytherapy, any type, each
Short description: Brachytherapy radioelements
HCPCS · United States
Medicare details
The indicators CMS publishes with Q3001 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Other carrier priced
- Type of service
- Medical care
- BETOS category
- Oncology - radiation therapy
- Added
- Jul 1, 2000
Where Q3001 sits
- 1Q codesTemporary codes
- 2Active code Q3001Radioelements for brachytherapy, any type, each
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q3001 mean?
Q3001 is the HCPCS code for “Radioelements for brachytherapy, any type, each” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q3001?
CMS lists Q3001’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Other carrier priced”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q3001
All Q codesQ2053Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2054Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2055Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per…Q2056Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures…Q2057Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic doseQ2058Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusionQ3014Telehealth originating site facility feeQ3027Injection, interferon beta-1a, 1 mcg for intramuscular useQ3028Injection, interferon beta-1a, 1 mcg for subcutaneous useQ3031Collagen skin testQ4001Casting supplies, body cast adult, with or without head, plasterQ4002Cast supplies, body cast adult, with or without head, fiberglass